26.04.2019 BB BIOTECH AG  CH0038389992

DGAP-Adhoc: BB Biotech AG reports results


 

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG reports results

26-Apr-2019 / 06:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Media Release, April 26, 2019
 

BB Biotech AG reports results


In accordance with regulations on ad hoc publicity, BB Biotech AG is releasing the following information about its results of the interim financial statements as of March 31, 2019.

Based on consolidated results, BB Biotech AG reports for the first quarter a profit of CHF 890 mn (profit of CHF 28 mn in the corresponding period of the previous year) was incurred. As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.

Since beginning of the year, BB Biotech AG's share price increased 24.2% in CHF and 25.4% in EUR.

The interim report as of March 31, 2019 will be published on April 26, 2019 at 7 am.


For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch

www.bbbiotech.com

 

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.


26-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
EQS News ID: 803465

 
End of Announcement DGAP News Service

803465  26-Apr-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=803465&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 324,56 775,68 1.392,56 616,82 8,84 624,17 5,13 0,00
EBITDA1,2 304,81 760,23 1.365,47 602,92 -746,78 588,33 -418,21 0,00
EBITDA-Marge3 93,91 98,01 98,05 97,75 -8.447,74 94,26 -8.152,24 0,00
EBIT1,4 304,81 760,23 1.365,47 602,92 -746,78 588,33 -418,21 0,00
EBIT-Marge5 93,91 98,01 98,05 97,75 -8.447,74 94,26 -8.152,24 0,00
Jahresüberschuss1 304,56 760,12 1.365,40 602,85 -747,71 587,80 -418,27 0,00
Netto-Marge6 93,84 97,99 98,05 97,74 -8.458,26 94,17 -8.153,41 0,00
Cashflow1,7 111,50 95,50 112,98 48,36 107,46 225,26 95,66 0,00
Ergebnis je Aktie8 5,10 13,34 24,11 10.79 -13,51 10,62 -7,55 4,70
Dividende8 0,73 1,15 2,36 2,63 2,58 2,85 2,68 2,50
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
BB Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0NFN3 59,000 Kaufen 3.495,75
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
14,05 4,84 2,937 13,20
KBV KCV KUV EV/EBITDA
1,42 36,54 681,43 -8,705
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
Hauptversammlung
2,68 2,50 4,54 19.03.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
24.04.2020 24.07.2020 18.10.2019 21.02.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
3,45% -0,75% 13,68% 8,26%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu BB BIOTECH AG  ISIN: CH0038389992 können Sie bei DGAP abrufen

Biotechnologie , A0NFN3 , BBZA , XETR:BBZA